When was Synendos Therapeutics founded?

Synendos Therapeutics was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Synendos Therapeutics located?

Synendos Therapeutics is headquartered in Allschwil, Switzerland. It is registered at Barfüsserplatz 3, 4051 Basel, CH.

Who is the current CEO of Synendos Therapeutics?

Andrea Chicca of Synendos Therapeutics. They have also founded 1 company.

How many employees does Synendos Therapeutics have?

As of Jul 31, 2026, the latest employee count at Synendos Therapeutics is 17.

Is Synendos Therapeutics a funded company?

Synendos Therapeutics is a funded company, having raised a total of $26.2M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 22, 2019.

When was the latest funding round of Synendos Therapeutics?

Synendos Therapeutics' latest funding was a $***** Series A round on Apr 20, 2021, with participation from 1 investor.

Where does Synendos Therapeutics rank among its competitors?

Synendos Therapeutics ranks 1st amongst 7 active competitors, of which 2 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Ajna, which secured $2.11M in May, 2024.

Who are the top competitors of Synendos Therapeutics?

Synendos Therapeutics' top competitors include Harvest Connect, Ajna and CanaQuest Medical. Among them, Ajna secured the most recent funding round in May, 2024.

Synendos Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Synendos Therapeutics is a developer of endocannabinoid modulators for the treatment of CNS disorders. It has developed pharmaceutical products to restore the natural function of the brain and treat neuropsychiatric disorders. The company is developing small molecules as selective endocannabinoid reuptake inhibitors that increase the levels of endogenous cannabinoids to treat CNS disorders caused by cannabinoid deficiency.

Website: synendos.com
Social
Email ID: *****@synendos.com
Registered Address: Barfüsserplatz 3, 4051 Basel, CH

Key Metrics

Founded Year

2019

Location

Allschwil, Switzerland

Stage

Series A

Total Funding

$26.2M in 5 rounds

Latest Funding Round

Series A, Apr 20, 2021, $*****

Investors

Sunstone & 12 more

Ranked

1^st among 7 active competitors

Employee Count

17 as on Jul 31, 2026

Similar Companies

Harvest Connect & 5 more

View Synendos Therapeutics' full profile

Synendos Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Synendos Therapeutics AG CIN: 1391442 , Switzerland, Active	Jun 22, 2023	-	-	-

Synendos Therapeutics has raised a total funding of $26.2M over 5 rounds. Its first funding round was on Jan 22, 2019. Its latest funding round was a Series A round on Apr 20, 2021 for $*****. 1 investor participated in its latest round. Synendos Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Synendos Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 20, 2021	1981172	Series A	6555631	1410136	7619954	3317118
Nov 11, 2020	5480093	Series A	1256057	5032163	6127027	Schroders Capital & 5 more
Jan 31, 2020	6965441	Grant (prize money)	4632394	7982808	7600648	EIC Fund

Access funding benchmarks and valuations. Sign up today!

View details of Synendos Therapeutics's funding rounds and investors

The founders of Synendos Therapeutics are Simon Russell Bird, Andrea Chicca and Jurg Gertsch. Andrea Chicca is the CEO of Synendos Therapeutics.

Here are the details of Synendos Therapeutics' key team members:

Simon Russell Bird: Co-founder and Chief Commercial Officer of Synendos Therapeutics. They serve on the board of 1 company.
Andrea Chicca: Co-Founder & CEO of Synendos Therapeutics.
Contact Info: 1 email address
Jurg Gertsch: Co-Founder of Synendos Therapeutics.

View details of Synendos Therapeutics's Founder profiles and Board Members

Synendos Therapeutics' employee count trend

Synendos Therapeutics has 17 employees as of Jul 26. Here is Synendos Therapeutics's employee count trend over the years:

Employee count trend for Synendos Therapeutics

Uncover Synendos Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Synendos Therapeutics include Harvest Connect, Ajna and CanaQuest Medical. Here is the list of Top 10 competitors of Synendos Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synendos Therapeutics 2019, Allschwil (Switzerland), Series A	Developer of endocannabinoid modulators for the treatment of CNS disorders	$26.2M	Sunstone, Schroders Capital & 11 others	59/100
2nd	Harvest Connect 2018, Roswell (United States), Seed	Developer of plant-based medicine and therapeutic psychedelics for general wellness and mental health	$725K	-	28/100
3rd	Ajna 2021, Littleton (United States), Funding Raised	Botanical drug development company focused on creating pharmaceutical-grade psychedelic extracts for the treatment of mental health and neurological disorders.	-	PhiFund Ventures	27/100
4th	CanaQuest Medical 2008, Mississauga (Canada), Public	Developer of pharmaceutical products targeting neurological disorders and mental health	$30.7K	Goldfingr	25/100
5th	VitalPoint Technologies 2023, Houston (United States), Unfunded	Developer of therapeutics for mental health and wellness	-	-	24/100
6th	Apurano Pharmaceuticals 2014, Warngau (Germany), Unfunded	Provider of smart bio-nanotechnology pharmaceutical products for multiple diseases	-	DI Mittelstand	20/100
7th	Neural Life Sciences 2021, Mumbai (India), Unfunded	Developer of cannabis and hemp-based products focused on cognitive health	-	-	17/100